Non Small Cell Lung Cancer Clinical Trial
Official title:
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib
We hypothesize that Epidermal growth factor receptor tyrosine kinase inhibitors modulate
tumor changes that may be reflected in the alteration of serum proteins.
Study objectives are:
- To establish serum proteomic changes in patients with non-small cell lung cancer
(NSCLC) receiving erlotinib or gefitinib.
- To identify a serum protein profile that predicts erlotinib or gefitinib sensitivity or
resistance in NSCLC patients with and without EGFR mutations.
- To study the toxicity of erlotinib or gefitinib by correlating clinical toxicity with
serum protein profile.
Background:
Although some success has been achieved in identifying Epidermal growth factor receptor
(EGFR) mutations as a molecular predictive marker of response in patients with non-small
cell lung cancer (NSCLC), this strategy is likely only to be limited as not all responding
patients have a mutation in their tumor and conversely, not all patients with a mutation
were responders. Furthermore, as the development of resistance to EGFR tyrosine kinase
inhibitors (TKI) such as gefitinib, erlotinib is inevitable and poses a major clinical
problem due to limited therapeutic options, the identification of a molecular profile that
could predict sensitivity to erlotinib or gefitinib is warranted.
Hypothesis:
Using serum as an easily accessible biological fluid, we hypothesize that EGFR TKIs modulate
tumor changes that may be reflected in the alteration of serum proteins.
Objectives:
- To establish the serum proteomic changes in NSCLC patients receiving erlotinib or
gefitinib.
- To identify a serum protein profile that predicts erlotinib or gefitinib sensitivity or
resistance in NSCLC patients with and without EGFR mutations.
- To study the toxicity of erlotinib or gefitinib by correlating clinical toxicity with
serum protein profile.
Significance:
An extensive profiling of the molecular circuitry affected by EGFR TKIs would be helpful in
understanding the response and side effects of patients with NSCLC treated with erlotinib or
gefitinib and could guide therapy and thus improve patient outcome.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |